Westlake Village, United States
Angitia Biopharmaceuticals, founded in 2018 and headquartered in the United States, is a clinical-stage biotechnology company with a mission stated in its slogan: "Developing innovative medicines to address serious musculoskeletal diseases".
The company stands out in the Biopharma, Biotechnology, and Health Care industries. It aims to fill key therapeutic gaps through its robust pipeline of therapeutics targeting serious musculoskeletal conditions. With a strong team known for scientific rigor, Angitia is positioned to transform current treatment paradigms.
Riding the momentum of advancements since inception, the company recently secured a $40.00M Series B investment, finalized on February 28, 2024. This round was led by Yuekai Securities, underscoring investor confidence in their strategic trajectory and innovative potential.
